IJCM  Vol.10 No.3 , March 2019
Oscillating Mechanical Stimulation of the Craniocervical Region as Physical Therapy for Chronic Migraine: A Pilot Trial
ABSTRACT
Objective: We conducted a prospective trial of oscillating mechanical stimulation (OS) of the craniocervical region as treatment for drug-refractory chronic migraine (CM). Methods: Ten patients (8 women, 2 men; mean age 47.0 ± 15.1 years) were enrolled. The treatment was administered over an 8-week period to 13, 4, and 9 sites on the face and head, neck, and upper back, respectively, at 5- to 15-pound intensity. The primary outcome measure was the number of days patients suffered a migraine (hereafter “number of migraine days”), and the secondary outcome measures were the six-item Headache Impact Test (HIT-6) and Visual Analog Scale (VAS) scores for migraine pain intensity and the nine-item Patient Health Questionnaire (PHQ-9) and the seven-item Generalized Anxiety Disorder (GAD-7) scale scores. Results: Nine patients completed treatment. The number of migraine days remained unchanged, from a mean 21.7 ± 11.6 days/month before treatment to 19.3 ± 7.3 days/month upon completion of treatment. However, the HIT-6 scores improved from 67.0 ± 8.2 to 61.4 ± 7.1 (p = 0.007) after 3 weeks, 61.1 ± 11.5 (p = 0.01) after 6 weeks, and 59.9 ± 11.6 (p = 0.035) upon completion of treatment. Similarly, the VAS scores improved significantly from 7.3 ± 1.7 to 5.7 ± 3.1 (p = 0.018) at 6 weeks and 4.8 ± 2.8 (p = 0.011) upon completion of treatment. The GAD-7, PHQ-9, and allodynia scale scores remained unchanged. Conclusion: Our data suggest that OS is well tolerated and may become a feasible form of treatment for drug-resistant CM.
Cite this paper
Shiraishi, M. , Hotta, M. , Suzuki, T. and Imai, N. (2019) Oscillating Mechanical Stimulation of the Craniocervical Region as Physical Therapy for Chronic Migraine: A Pilot Trial. International Journal of Clinical Medicine, 10, 150-160. doi: 10.4236/ijcm.2019.103015.
References
[1]   Headache Classification Committee of the International Headache Society (HIS) (2013) The International Classification of Headache Disorders. 3rd Edition (Beta Version). Cephalalgia, 33, 629-808.

[2]   Wang, S.J., Fuh, J.L., Lu, S.R., et al. (2000) Chronic Daily Headache in Chinese Elderly: Prevalence, Risk Factors, and Biannual Follow-Up. Neurology, 54, 314-319.
https://doi.org/10.1212/WNL.54.2.314

[3]   Martelletti, P., Katsarava, Z., Lampl, C., et al. (2014) Refractory Chronic Migraine: A Consensus Statement on Clinical Definition from the European Headache Federation. The Journal of Headache and Pain, 15, 47.
https://doi.org/10.1186/1129-2377-15-47

[4]   Lanteri-Minet, M. (2014) Economic Burden and Costs of Chronic Migraine. Current Pain and Headache Reports, 18, 385.
https://doi.org/10.1007/s11916-013-0385-0

[5]   Aurora, S.K., Dodick, D.W., Turkel, C.C., et al., PREEMPT 1 Chronic Migraine Study Group (2010) Onbotulinumtoxin A for Treatment of Chronic Migraine: Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT 1 Trial. Cephalalgia, 30, 793-803.
https://doi.org/10.1177/0333102410364676

[6]   Diener, H.C., Dodick, D.W., Aurora, S.K., et al. (2014) Onbotulinumtoxin A for Treatment of Chronic Migraine; Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT 2 Trial. Cephalalgia, 30, 804-814.
https://doi.org/10.1177/0333102410364677

[7]   Schoenen, J., Vandersmissen, B., Jeangette, S., et al. (2013) Migraine Prevention with a Supraorbital Transcutaneous Stimulator: A Randomized Controlled Trial. Neurology, 80, 697-704.
https://doi.org/10.1212/WNL.0b013e3182825055

[8]   Hotta, M., Shiraishi, M., Suzuki, T., Nishiyma, T. and Imai, N. (2016) Preliminary Study on the Effectiveness of Physical Therapy by Craniocervical Oscillating Stimulation for Chronic Headaches. Japanese Journal of Headache, 42, 177-181.

[9]   Bannuru, R.R., Falvin, N.E., Vaysbrot, E., Harvey, W. and McAlindon, T. (2014) High-Energy Extracorporeal Shock-Wave Therapy for Treating Chronic Calcific Tendinitis of the Shoulder: A Systematic Review. Annals of Internal Medicine, 160, 542-549.
https://doi.org/10.7326/M13-1982

[10]   International Headache Society (2014) International Classification of Headache Disorders, 3rd Edition (Beta Version). Igaku-Shoin Ltd., Tokyo, 10-11.

[11]   Clinical Practice Guideline for Chronic Headache 2013 (2014) Lists of Members of Chronic Headache Clinical Practice Guideline Development Committee, Members of Evaluation and Coordination Committee, Collaborating Societies. Igaku-Shoin Ltd., Tokyo, 114-117.

[12]   Kosinski, M., Bayliss, M.S., Bjorner, J.B., et al. (2003) A Six-Item Short-Form Survey for Measuring Headache Impact: The HIT-6. Quality of Life Research, 12, 963-974.
https://doi.org/10.1023/A:1026119331193

[13]   Katz, J. and Melzack, R. (1999) Measurement of Pain. Surgical Clinics of North America, 79, 231-252.
https://doi.org/10.1016/S0039-6109(05)70381-9

[14]   Muramatsu, K., Miyaoka, H., Kamijima, K., et al. (2007) The Patient Health Questionnaire, Japanese Version: Validity According to the Mini-International Neuropsychiatric Interview-Plus. Psychological Reports, 101, 952-960.

[15]   Spitzer, R.L., Kroenke, K., Williams, J.B. and Löwe, B. (2006) A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine, 22, 1092-1097.
https://doi.org/10.1001/archinte.166.10.1092

[16]   Kinfe, T.M., Pintea, B., Muhammad, S., et al. (2015) Cervical Non-Invasive Vagus Nerve Stimulation (nVNS) for Preventive and Acute Treatment of Episodic and Chronic Migraine and Migraine-Associated Sleep Disturbance: Preliminary Findings from a Prospective Observational Cohort Study. The Journal of Headache and Pain, 16, 101.
https://doi.org/10.1186/s10194-015-0582-9

[17]   Smith, G.S., Savery, D., Marden, C., et al. (1994) Distribution of Messenger RNAs Encoding Enkephalin, Substance P, Somatostatin, Galanin, Vasoactive Intestinal Polypeptide, Neuropeptide Y, and Calcitonin Gene-Related Peptide in the Midbrain Periaqueductal Grey in the Rat. Journal of Comparative Neurology, 350, 23-40.
https://doi.org/10.1002/cne.903500103

[18]   Welch, K.M., Nagesh, V., Aurora, S.K. and Gelman, N. (2001) Periaqueductal Gray Matter Dysfunction in Migraine: Cause or the Burden of Illness? Headache, 41, 629-637.
https://doi.org/10.1046/j.1526-4610.2001.041007629.x

[19]   Burstein, R. and Jakubowski, M. (2004) Analgesic Triptan Action in an Animal Model of Intracranial Pain: A Race against the Development of Central Sensitization. Annals of Neurology, 55, 27-36.
https://doi.org/10.1002/ana.10785

[20]   Yarnitsky, D., Goor-Aryeh, I., Bajwa, Z.H., et al. (2003) 2003 Wolff Award: Possible Parasympathetic Contribution to Peripheral and Central Sensitization during Migraine. Headache, 43, 704-714.
https://doi.org/10.1046/j.1526-4610.2003.03127.x

[21]   Chandler, M.J., Hobbs, S.F., Bloser, D.C. and Foreman, R.D. (1991) Effects of Vagal Afferent Stimulation on Cervical Spinothalamic Tract Neurons in Monkeys. Pain, 44, 81-87.
https://doi.org/10.1016/0304-3959(91)90152-N

[22]   Reed, K.L., Black, S.B., Banta, C.J. and Will, K.R. (2010) Combined Occipital and Supraorbital Neurostimulation for the Treatment of Chronic Migraine Headaches: Initial Experience. Cephalgia, 30, 260-271.
https://doi.org/10.1111/j.1468-2982.2009.01996.x

[23]   Welch, K.M., Cao, Y., Aurora, S.K., Wiggins, G. and Vikingstad, E.M. (1998) MRI of the Occipital Cortex, Red Nucleus and Substantia Nigra during Visual Aura of Migraine. Neurology, 51, 1465-1469.
https://doi.org/10.1212/WNL.51.5.1465

[24]   Weiller, C., May, A., Limmroth, V., et al. (1995) Brain Stem Activation in Spontaneous Human Migraine Attacks. Nature Medicine, 1, 658-660.
https://doi.org/10.1038/nm0795-658

 
 
Top